Search
Search results
1498 results found
Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol 2019;18:145-154.
LeWitt, PA, RA Hauser, R Pahwa, SH Isaacson, HH Fernandez, M Lew, M Saint-Hilaire, et al. 2019. “Safety and Efficacy of CVT-301 (levodopa Inhalation Powder) on Motor Function During off Periods in Patients With Parkinson’s Disease: A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial. Lancet Neurol 2019;18:145-154.”. Lancet Neurol.
Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease. Parkinsonism Relat Disord 2019;64:175-180.
Hauser, RA, SH Isaacson, A Ellenbogen, BE Safirstein, DD Truong, SF Komjathy, DM Kegler-Ebo, P Zhao, and C Oh. 2019. “Orally Inhaled Levodopa (CVT-301) for Early Morning OFF Periods in Parkinson’s Disease. Parkinsonism Relat Disord 2019;64:175-180.”. Parkinsonism Relat Disord.
Prevalence of Dyskinesia and OFF by 30-minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials. J Parkinsons Dis 2019;9:591-600.
Hauser, RA, DE Kremens, LW Elmer, DL Kreitzman, RR Walsh, R Johnson, R Howard, JT Nguyen, and R Patni. 2019. “Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials. J Parkinsons Dis 2019;9:591-600.”. J Parkinsons Dis.
Using global team science to identify genetic parkinson's disease worldwide. Ann Neurol 2019;86:153-157.
Vollstedt, EJ, M Kasten, C Klein, and MJFF Global Genetic Parkinson’s Disease Study Group. 2019. “Using Global Team Science to Identify Genetic Parkinson’s Disease Worldwide. Ann Neurol 2019;86:153-157.”. Ann Neurol.
Impact of non-motor symptoms in Parkinson's disease: a PMDAlliance survey. Neuropsychiatr Dis Treat 2019;15:2205-2212.
Hermanowicz, N, SA Jones, and RA Hauser. 2019. “Impact of Non-Motor Symptoms in Parkinson’s Disease: A PMDAlliance Survey. Neuropsychiatr Dis Treat 2019;15:2205-2212.”. Neuropsychiatry Dis Treat.
Frei K, Truong DD, Fahn S, Jankovic J, Hauser RA. The nosology of tardive syndromes. J Neurol Sci 2018;389:10-16.
Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. J Neurol Neurosurg Psychiatry 2013;84:1288-95.
Bajaj, N, RA Hauser, and ID Grachev. 2013. “Clinical Utility of Dopamine Transporter Single Photon Emission CT (DaT-SPECT) With (123I) Ioflupane in Diagnosis of Parkinsonian Syndromes. J Neurol Neurosurg Psychiatry 2013;84:1288-95.”. J Neurol Neurosurg Psychiatry.
[123I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected Parkinsonian syndromes. J Neuroimaging 2012;22:225-30.
Hauser, RA, and DG Grosset. 2012. “[123I]FP-CIT (DaTscan) SPECT Brain Imaging in Patients With Suspected Parkinsonian Syndromes. J Neuroimaging 2012;22:225-30.”. J Neuroimaging.
The UPDRS-8: a brief clinical assessment scale for Parkinson's disease. Int J Neurosci 2012;122:333-7.
Hauser, RA, KE Lyons, and R Pahwa. 2012. “The UPDRS-8: A Brief Clinical Assessment Scale for Parkinson’s Disease. Int J Neurosci 2012;122:333-7.”. Int J Neurosci.